Alphyn Biologics

About Alphyn Biologics

Alphyn Biologics is a life science company focused on developing breakthrough therapies for severe and common skin diseases. Their mission is to improve the lives of millions of patients worldwide by creating first-in-class, Multi-Target Therapeutics (MTT™) that are safe, powerful, and effective in treating challenging skin conditions.

Products & Services

Zabalafin Hydrogel (AB-101a):A steroid-free topical treatment for mild-to-moderate atopic dermatitis (AD), targeting immune system and bacterial components with minimal side effects and high patient tolerability, aiming to be the first complete therapeutic for AD.

Zabalafin Platform (AB-101 Drug Platform):A proprietary platform with multiple bioactive compounds to develop Multi-Target Therapeutics capable of addressing multiple diseases and their symptoms/causes.

Specialties

Skin disease therapies Atopic Dermatitis treatment Multi-Target Therapeutics (MTT™) Topical botanical drugs

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 25000000 MR: - FA: $25 million FAN: 25000000	D: 2025-12-12 FD: 2025-12-12	5 investors

Series B Latest

2025-12-12

$25.0M

5 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

G

Gary Pekoe

Chief Scientific Officer

N

Neal Koller

CEO

S

Steven Pentelnik

President

J

Jim Darnell

Vice President of Quality

J

Jazmyne Mink

Regulatory Affairs Director

R

Rich Panico

Business Development and Clinical Trials Advisor

View 11 more team members with Pro

Unlock Full Team Directory

Recent News